Research and Markets: Atherosclerosis - Pipeline Review, H1 2013

Thu Apr 4, 2013 5:18am EDT

* Reuters is not responsible for the content in this press release.

DUBLIN--(Business Wire)--

Research and Markets

( has
announced the addition of the "Atherosclerosis - Pipeline Review, H1 2013"
report to their offering. 

Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H1 2013', provides
an overview of the indication's therapeutic pipeline. This report provides
information on the therapeutic development for Atherosclerosis, complete with
latest updates, and special features on late-stage and discontinued projects. It
also reviews key players involved in the therapeutic development for


- A snapshot of the global therapeutic scenario for Atherosclerosis. 

- A review of the Atherosclerosis products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources. 

- Coverage of products based on various stages of development ranging from
discovery till registration stages. 

- A feature on pipeline projects on the basis of monotherapy and combined

- Coverage of the Atherosclerosis pipeline on the basis of route of
administration and molecule type. 

- Key discontinued pipeline projects. 

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under
development for Atherosclerosis. 

- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. 

- Devise corrective measures for pipeline projects by understanding
Atherosclerosis pipeline depth and focus of Indication therapeutics. 

- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope. 

- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.